???global.info.a_carregar???
I have graduated in Biotechnology Engineering in 2003 by Instituto Politécnico de Bragança. After that, I moved to Porto to develop a Master Degree in Molecular Oncology (Faculty of Medicine, University of Porto) at IPATIMUP, in collaboration with Michael Hollingsworth's lab at the University of Nebraska Medical Center (Omaha, USA), where part of the MSc project was developed. This first contact with cancer research set a stone in my professional career, leading me to pursue a PhD in Biomedical Sciences at the School of Medicine and Biological Sciences (ICBAS, University of Porto). For that purpose, I was accepted at the Cancer Genetics Group of IPO Porto, led by Professor Manuel Teixeira, where I started my scientific career in prostate cancer. I have completed my PhD in 2011, in tight collaboration with Ragnhild Lothe's lab at the Oslo University Hospital (Olso, Norway), establishing the existence of different molecular subtypes of prostate cancer considering the presence of genomic rearrangements involving members of the ETS family of transcription factors. I have also contributed to the identification of new genomic rearrangements involving other ETS members and rearrangement partners. Since 2019, I am an Assistant Researcher at the Cancer Genetics Group of IPO Porto, specialised in molecular and cellular biology of prostate cancer (Scopus h-index 23). My main research focus is the identification of genetic alterations in prostate cancer with potential utility for the diagnosis and treatment of the patients. I use different molecular as biological approaches to assess the oncogenic role of genetic changes found in the germline of patients with criteria for hereditary disease or the impact of somatic alterations. I am particularly interested in the identification of new therapeutic approaches for specific molecular changes/cancer subtypes and in understanding the role of the immune system in therapeutic efficacy. I have authored/co-authored 47 articles in international peer-reviewed scientific journals and been involved in the supervision/co-supervision 4 PhD Thesis and 10 Master Thesis. I am member of the International Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) and of the Advisory and Editorial Boards of the peer-reviewed scientific journals "International Journal of Molecular Sciences" and "Current Issues in Molecular Biology", respectively.
Read full resume ↓
Identification

Personal identification

Full name
Paula Cristina Martins Santos Paulo

Citation names

  • Paulo, Paula

Author identifiers

Ciência ID
F514-C818-E2FF
ORCID iD
0000-0001-8387-2127
Researcher Id
F-1441-2016
Scopus Author Id
55349129300

Email addresses

  • paula.paulo@ipoporto.min-saude.pt (Professional)

Telephones

Telephone
  • 225084000 Ext.: 5609 (Professional)

Addresses

  • IPO Porto Research Centre (CI-IPOP, R&D unit 776). Rua Dr. António Bernardino Almeida, 4200-072, Porto, Porto, Portugal (Professional)

Websites

Knowledge fields

  • Medical and Health Sciences - Medical Biotechnology - Health-Related Biotechnology
  • Medical and Health Sciences - Health Sciences

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Norwegian Beginner (A1) Beginner (A1) Beginner (A1) Beginner (A1)
Education
Degree Classification
2012/04/01 - 2018/06/30
Concluded
 PostDoc in Oncogenetics (Pós-doutoramento)
Major in Oncogenetics
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2007/10/24 - 2011/10/24
Concluded
 PhD in Biomedical Sciences (Doutoramento)
Major in Biomedical Sciences
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Fusion oncogenes involving the ETS family of transcription factors in prostate cancer: target genes and clinical applications" (THESIS/DISSERTATION)
 Very Good with Distinction
2004/01/01 - 2006/10/27
Concluded
 Master in Molecular Oncology (Mestrado)
Universidade do Porto Faculdade de Medicina, Portugal
"MUC1 mucin silencing in gastric carcinoma - establishment of an in vitro cell model" (THESIS/DISSERTATION)
 Very Good
1998/09/12 - 2003/11/26
Concluded
 Biotechnology Engineering (Licenciatura)
Instituto Politécnico de Bragança Escola Superior Agrária, Portugal
"Polimorfismos do gene GABABR1 na Epilepsia Idiopática Generalizada" (THESIS/DISSERTATION)
 16
Affiliation

Science

Category
Host institution 		Employer
2019/05/01 - Current Auxiliary Researcher (Research) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2012/07/01 - 2018/12/31 Postdoc (Research) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2007/11/01 - 2010/10/31 Researcher (Research) Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2004/11/01 - 2007/10/31 Researcher (Research) Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal

Teaching in Higher Education

Category
Host institution 		Employer
2023/09/04 - Current Visiting Professor (University Teacher) Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil EPE - Escola Portuguesa de Oncologia do Porto, Portugal
(...)

Positions / Appointments

Category
Host institution 		Employer
2021/03/01 - Current Responsible for the management of the laboratory Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Projects

Grant

Designation Funders
2023/01/01 - Current Theragnostic exploitation of ciliogenesis defects in prostate cancer- building bridges
CI-IPOP 155-2021
Principal investigator
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Ongoing
2023/01/01 - Current Identification of markers of resistance to anti-EGFR therapy in colorectal carcinoma
CI-IPOP 08-2023
Principal investigator
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Ongoing
2023/01/01 - Current In vitro exploitation of the therapeutic potential of EGFR pathway inhibitors in prostate cancer cells harboring ETS rearrangements
CI-IPOP 30-2023
Principal investigator
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Ongoing
2007/10/01 - 2010/09/30 Characterization of fusion genes involving the ETS family of transcription factors and their role as diagnostic and prognostic markers in prostate cancer
SFRH/BD/27669/2006
PhD Student Fellow
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2004/05/01 - 2006/10/31 Clarification of the biological role of MUC1 mucin variability in gastric carcinogenesis
POCTI/CBO/44812/2002
Research Fellow
Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded

Contract

Designation Funders
2023/01/01 - Current REVERENT: Pre-clinical validation of a glycocode-inspired vaccine for bladder cancer immunotherapy
2022.03621.PTDC
Researcher
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Ongoing
2021/01/01 - Current Rede de Investigação em Saúde: do Laboratório à Saúde Comunitária
LA/P/0053/2020
Researcher
Universidade do Porto Unidade de Investigação e Desenvolvimento Cardiovascular, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Algarve, Portugal

Universidade do Porto Faculdade de Ciências, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade da Madeira, Portugal

Universidade de Lisboa Centro Cardiovascular da Universidade de Lisboa, Portugal

Centro de Investigação em Tecnologias e Serviços de Saúde, Portugal

Universidade do Porto Faculdade de Medicina, Portugal

Associação para a Investigação e Desenvolvimento da Faculdade de Medicina, Portugal

Escola Superior de Enfermagem do Porto, Portugal

Universidade de Aveiro, Portugal

Universidade NOVA de Lisboa, Portugal
Fundação para a Ciência e a Tecnologia
Ongoing
2021/01/01 - Current Health Research Network: From Lab to Community Health
10.54499/LA/P/0053/2020
Researcher
Universidade do Porto Unidade de Investigação e Desenvolvimento Cardiovascular, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Algarve, Portugal

Universidade do Porto Faculdade de Ciências, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade da Madeira, Portugal

Universidade de Lisboa Centro Cardiovascular da Universidade de Lisboa, Portugal

Centro de Investigação em Tecnologias e Serviços de Saúde, Portugal

Universidade do Porto Faculdade de Medicina, Portugal

Associação para a Investigação e Desenvolvimento da Faculdade de Medicina, Portugal

Escola Superior de Enfermagem do Porto, Portugal

Universidade de Aveiro, Portugal

Universidade NOVA de Lisboa, Portugal
Fundação para a Ciência e a Tecnologia
Ongoing
2020/01/01 - Current IPO Porto Research Center
UIDP/00776/2020
10.54499/UIDP/00776/2020
Researcher
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
2019/01/01 - Current Centro de Investigação do Instituto Português de Oncologia do Porto
UID/DTP/00776/2019
Researcher
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2018/07/26 - 2021/11/21 SEGMAPP: The role of chromosome segregation machinery defects in genetic predisposition to prostate cancer
PTDC/MED-GEN/28245/2017
Principal investigator
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal

Universidade do Porto Instituto de Investigação e Inovação em Saúde, Portugal

Rede de Química e Tecnologia Laboratório Associado para a Química Verde, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
2016/07/01 - 2018/12/31 Inherited predisposition to prostate cancer: finding the missing heritability by combining exome sequencing and haplotype analyses in a population with strong founder effects
PTDC/DTP-PIC/1308/2014
Post-doc Fellow
Instituto Português de Oncologia do Porto Francisco Gentil EPE, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2013/01/01 - 2013/12/31 Defining the oncogenic potential of GRPR overexpression in prostate carcinomas harboring ERG or ETV1 rearrangements and its role as therapy target
APU/JABA RECORDATI 2012
Principal investigator
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
 Associação Portuguesa de Urologia

Jaba Recordati SA
Concluded
2012/04/01 - 2013/12/31 Strategic Project - UI 776 - 2011-2012
Pest-OE/SAU/UI776/2011
Post-doc Fellow
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
Outputs

Publications

Conference abstract
  1. Paulo, Paula; Barros-Silva, JD; Ribeiro, FR; Carvalho, JR; Mesquita, B.; Jerónimo, Carmen; Henrique, Rui; et al. "Quantitative expression analysis of nine ETS transcription factors and of the MYC and PTEN genes in a consecutive series of 200 prostate carcinomas". Paper presented in 21st Meeting of the European Association for Cancer Research, Oslo, 2010.
    Published
  2. Ribeiro, FR; Paulo, Paula; Costa, VL; Barros-Silva, JD; Carvalho, JR; Mesquita, B.; Henrique, Rui; et al. "Downstream targets of the TMPRSS2-ERG rearrangement in prostate cancer: cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in fusion-positive carcinomas". Paper presented in 21st Meeting of the European Association for Cancer Research, Oslo, 2010.
    Published
  3. Santos-Silva, F.; Reis, Cassilda; Paulo, Paula; Caffrey, T.; David, Leonor; Hollingsworth, M.A.. "MUC1 polymorphism affects apoptotic levels and motility in a cancer cell line model". Paper presented in 96th Annual Meeting of the American Association for Cancer Research, Anaheim, 2005.
    Accepted
Conference poster
  1. Cruz, Pedro; Meneses, Olga; Ramos, Raquel; Brandão, Andreia; Veiga, Isabel; Rocha, Patricia; Henrique, Rui; et al. Corresponding author: Paulo, Paula. "Eficácia de anti-EGFR em cancro colorretal metastizado é aumentada pela sobreexpressão de EGFR ou ETV4 e reduzida pela de ETV5 ou ETV1". Paper presented in 3ª Edição do Concurso de Pósteres Científicos Revolution Poster Awards by Pierre Fabre, 2023.
  2. Dourado-Gonçalves, Martina; Freitas, Rui; Ferreira, Dylan; Relvas-Santos, Marta; Paulo, Paula; Lara Santos, Lúcio; Ferreira, José Alexandre; Peixoto, Andreia. "Functional Glycoproteomics Characterization of Gastric Cancer Cells Expressing Immature O-Glycans". Paper presented in 1st Young Researcher's Day, 2023.
  3. Paiva, Elsa; Orr, Bernard; Teixeira, Manuel R.; Paulo, Paula. Corresponding author: Paulo, Paula. "Molecular subtypes of prostate carcinomas may identify patients eligible for combined anti-EGFR/STAT3 therapy". Paper presented in 1st Young Researcher's Day, 2023.
  4. Ramos, Raquel Almeida; Brandão, Andreia; Cruz, Pedro; Meneses, Olga; Veiga, Isabel; Rocha, Patricia; Henrique, Rui; et al. Corresponding author: Paulo, Paula. "PEA3 transcription factors are prognostic biomarkers of response to anti-EGFR therapy in metastatic colorectal cancer". Paper presented in 1st Young Researcher's Day, 2023.
  5. Meneses, Olga; Cruz, Pedro; Ramos, Raquel; Brandão, Andreia; Veiga, Isabel; Rocha, Patricia; Henrique, Rui; et al. Corresponding author: Paulo, Paula. "Determinantes moleculares da eficácia terapêutica anti-EGFR no cancro colorretal metastizado". Paper presented in 20º Congresso Nacional de Oncologia, 2023.
  6. Silva, Maria P.; Ferreira, Luísa; Brás, Natércia; Torres, Lurdes; Brandão, Andreia; Pinheiro, Manuela; Cardoso, Marta; et al. Corresponding author: Paulo, Paula. "BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability". Paper presented in 26ª Reunião Anual da Sociedade Portuguesa de Genética Humana, 2022.
  7. Miranda, Andreia; Ferreira, Dylan; Freitas, Rui; Relvas-Santos, Marta; Palmeira, Carlos; Paulo, Paula; Castro, Flávia; et al. "Cancer-associated shor-chain O-GalNAc glycans induce an immunosupressive bladder cancer phenotype by impairing dendritic cells function. Trabalho apresentado no XLVII Annual Meeting of the Portuguese Society for Immunology". Paper presented in XLVII Annual Meeting of the Portuguese Society for Immunology, 2022.
  8. Silva, Maria P. ((9618-5B5D-E47A); Ferreira, Luisa; Torres, Lurdes; Brandão, Andreia; Pinheiro, Manuela; Palmeira, Carlos; Maiato, Helder; Paulo, Paula; Teixeira, Manuel R.. Corresponding author: Paulo, Paula. "A recurrent in-frame BUB1B germline variant in prostate cancer predisposition". Paper presented in EMBO Workshop: Systems Approaches in Cancer, 2021.
  9. Cardoso, M; Maia, S; Brandão, A; Peixoto, A; Santos, C; Paulo, Paula; Teixeira, MR (4D1D-1F29-9100). "Pathogenic variants in ATM and CHEK2 are more frequent than in BRCAs and HOXB13 in patients with hereditary prostate cancer". Paper presented in 2nd ASEICA EDUCATIONAL SYMPOSIUM, 2019.
  10. Brandão, A; Cardoso, M; Silva, MP; Peixoto, A; Pinheiro, M; Santos, C; PRACTICAL Consortium; Paulo, Paula; Teixeira, MR (4D1D-1F29-9100). "The tale of CHEK2 c.349A>G, a new founder variant associated with prostate cancer risk in populations of European ancestry". Paper presented in 2nd ASEICA EDUCATIONAL SYMPOSIUM, 2019.
  11. Paulo, Paula; Barros-Silva, JD; Costa, VL; Ribeiro, FR; Henrique, Rui; Jerónimo, Carmen; Teixeira, MR (4D1D-1F29-9100). "Alternative splicing of ERG and TMPRSS2-ERG type III rearrangement in prostate cancer". Paper presented in Jornadas de Oncologia do IPO Porto, 2009.
  12. Paulo, Paula (F514-C818-E2FF); Cerveira, Nuno; Santos, Joana; Pinheiro, Manuela; Costa, Vera L; Jerónimo, Carmen; Teixeira, Manuel R. "Alternative splicing of ERG and TMPRSS2:ERG rearrangement in prostate cancer cell lines". Paper presented in 11th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors, 2008.
  13. Paulo, Paula; Santos-Silva, L. "Relevance of MUC1 mucin silencing in gastric cancer cells phenotype: effect on mucins expression and glycosylation profile". Paper presented in XV Congreso Nacional de Bioquímica, 2006.
Journal article
  1. Paula Paulo; Marta Cardoso; Andreia Brandão; Pedro Pinto; Ariane Falconi; Manuela Pinheiro; Nuno Cerveira; et al. "Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients". Genes, Chromosomes and Cancer (2023): https://doi.org/10.1002/gcc.23190.
    10.1002/gcc.23190
  2. Wang, Anqi; Shen, Jiayi; Rodriguez, Alex A.; Saunders, Edward J.; Chen, Fei; Janivara, Rohini; Darst, Burcu F.; et al. "Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants". Nature Genetics (2023): http://dx.doi.org/10.1038/s41588-023-01534-4.
  3. Cardoso, Marta; Maia, Sofia; Brandão, Andreia; Sahasrabudhe, Ruta; Lott, Paul; Belter, Natalia; Carvajal-Carmona, Luis G.; Paulo, Paula; Teixeira, Manuel R.. "Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene". British Journal of Cancer 128 6 (2023): 1077-1085. http://dx.doi.org/10.1038/s41416-022-02125-6.
    10.1038/s41416-022-02125-6
  4. Silva, Maria P.; Ferreira, Luisa T; Bras, Natercia F.; Torres, Lurdes; Brandão, Andreia; Pinheiro, Manuela; Cardoso, Marta; et al. Corresponding author: Paulo, Paula. "Proceedings of the 26th Annual Meeting of the Portuguese Society of Human Genetics (SPGH – Sociedade Portuguesa de Genética Humana) Coimbra, 17–19 November 2022". Medicine 102 13 (2023): e33154. http://dx.doi.org/10.1097/md.0000000000033154.
    10.1097/md.0000000000033154
  5. Gaiteiro, Cristiana; Soares, Janine; Relvas-Santos, Marta; Peixoto, Andreia; Ferreira, Dylan; Brandão, Andreia; Elisabete Fernandes; et al. "Glycoproteogenomics characterizes the CD44 splicing code associate with bladder cancer invasion". Theranostics 12 7 (2022): 3150-3177.
    Published • 10.7150/thno.67409
  6. Peixoto, Andreia; Ferreira, Dylan; Azevedo, Rita; Freitas, Rui; Fernandes, Elisabete; Relvas-Santos, Marta; Gaiteiro, Cristiana; et al. "Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer". Journal of Experimental & Clinical Cancer Research 40 1 (2021): http://dx.doi.org/10.1186/s13046-021-01988-6.
    Open access • Published • 10.1186/s13046-021-01988-6
  7. Conti, David V.; Darst, Burcu F.; Moss, Lilit C.; Saunders, Edward J.; Sheng, Xin; Chou, Alisha; Schumacher, Fredrick R.; et al. "Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction". Nature Genetics 53 1 (2021): 65-75. http://dx.doi.org/10.1038/s41588-020-00748-0.
    10.1038/s41588-020-00748-0
  8. Karlsson, Questa; Brook, Mark N.; Dadaev, Tokhir; Wakerell, Sarah; Saunders, Edward J.; Muir, Kenneth; Neal, David E.; et al. "Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study". European Urology Oncology (2021): http://dx.doi.org/10.1016/j.euo.2020.12.001.
    10.1016/j.euo.2020.12.001
  9. Conti DV; Darst BF; Moss LC; Saunders EJ; Sheng X; Chou A; Schumacher FR; et al. "Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.". Nature genetics (2021): http://europepmc.org/abstract/med/33473200.
    10.1038/s41588-021-00786-2
  10. Brandão, Andreia; Paulo, Paula; Maia, Sofia; Pinheiro, Manuela; Peixoto, Ana; Cardoso, Marta; Silva, Maria P.; et al. "The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor". Cancers 12 11 (2020): 3254. http://dx.doi.org/10.3390/cancers12113254.
    10.3390/cancers12113254
  11. Brandão, Andreia; Paulo, Paula; Teixeira, Manuel R.. "Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications". International Journal of Molecular Sciences 21 14 (2020): 5036. http://dx.doi.org/10.3390/ijms21145036.
    10.3390/ijms21145036
  12. Huynh-Le, Minh-Phuong; Fan, Chun Chieh; Karunamuni, Roshan; Walsh, Eleanor I.; Turner, Emma L.; Lane, J. Athene; Martin, Richard M.; et al. "A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data". Cancer Epidemiology Biomarkers & Prevention 29 9 (2020): 1731-1738. http://dx.doi.org/10.1158/1055-9965.epi-19-1527.
    10.1158/1055-9965.epi-19-1527
  13. Schumacher FR; Olama AAA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; et al. "Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.". Nature genetics (2019): http://europepmc.org/abstract/med/30622367.
    10.1038/s41588-018-0330-6
  14. Matejcic M; Saunders EJ; Dadaev T; Brook MN; Wang K; Sheng X; Olama AAA; et al. "Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry.". Nature communications (2019): http://europepmc.org/abstract/med/30655571.
    10.1038/s41467-019-08293-z
  15. Matejcic, Marco; Saunders, Edward J.; Dadaev, Tokhir; Brook, Mark N.; Wang, Kan; Sheng, Xin; Olama, Ali Amin Al; et al. "Germline variation at 8q24 and prostate cancer risk in men of European ancestry". Nature Communications 9 1 (2018): http://dx.doi.org/10.1038/s41467-018-06863-1.
    10.1038/s41467-018-06863-1
  16. Dadaev, Tokhir; Saunders, Edward J.; Newcombe, Paul J.; Anokian, Ezequiel; Leongamornlert, Daniel A.; Brook, Mark N.; Cieza-Borrella, Clara; et al. "Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants". Nature Communications 9 1 (2018): http://dx.doi.org/10.1038/s41467-018-04109-8.
    10.1038/s41467-018-04109-8
  17. Schumacher, Fredrick R.; Al Olama, Ali Amin; Berndt, Sonja I.; Benlloch, Sara; Ahmed, Mahbubl; Saunders, Edward J.; Dadaev, Tokhir; et al. "Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci". Nature Genetics 50 7 (2018): 928-936. http://dx.doi.org/10.1038/s41588-018-0142-8.
    10.1038/s41588-018-0142-8
  18. Paulo, Paula; Maia, Sofia; Pinto, Carla; Pinto, Pedro; Monteiro, Augusta; Peixoto, Ana; Teixeira, Manuel R.. "Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer". PLOS Genetics 14 4 (2018): e1007355-e1007355. https://doi.org/10.1371/journal.pgen.1007355.
    10.1371/journal.pgen.1007355
  19. Seibert, Tyler M; Fan, Chun Chieh; Wang, Yunpeng; Zuber, Verena; Karunamuni, Roshan; Parsons, J Kellogg; Eeles, Rosalind A; et al. "Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts". BMJ (2018): j5757. http://dx.doi.org/10.1136/bmj.j5757.
    10.1136/bmj.j5757
  20. Paulo, Paula; Pinto, Pedro; Peixoto, Ana; Santos, Catarina; Pinto, Carla; Rocha, Patrícia; Veiga, Isabel; et al. "Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes". The Journal of Molecular Diagnostics 19 4 (2017): 502-513. http://dx.doi.org/10.1016/j.jmoldx.2017.05.001.
    10.1016/j.jmoldx.2017.05.001
  21. Cardoso, Marta; Maia, Sofia; Paulo, Paula; Teixeira, Manuel R.. "Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis". Oncoscience 3 9-10 (2016): 288-296. http://dx.doi.org/10.18632/oncoscience.322.
    10.18632/oncoscience.322
  22. Luedeke, Manuel; Rinckleb, Antje E.; FitzGerald, Liesel M.; Geybels, Milan S.; Schleutker, Johanna; Eeles, Rosalind A.; Teixeira, Manuel R.; et al. "Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status". Human Molecular Genetics (2016): ddw349. http://dx.doi.org/10.1093/hmg/ddw349.
    10.1093/hmg/ddw349
  23. Pinto, Pedro; Paulo, Paula; Santos, Catarina; Rocha, Patrícia; Pinto, Carla; Veiga, Isabel; Pinheiro, Manuela; Peixoto, Ana; Teixeira, Manuel R.. "Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity". Breast Cancer Research and Treatment 159 2 (2016): 245-256. http://dx.doi.org/10.1007/s10549-016-3948-z.
    10.1007/s10549-016-3948-z
  24. Kar, Siddhartha P.; Beesley, Jonathan; Amin Al Olama, Ali; Michailidou, Kyriaki; Tyrer, Jonathan; Kote-Jarai, ZSofia; Lawrenson, Kate; et al. "Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types". Cancer Discovery 6 9 (2016): 1052-1067. http://dx.doi.org/10.1158/2159-8290.cd-15-1227.
    10.1158/2159-8290.cd-15-1227
  25. Cardoso M; Paulo P; Maia S; Teixeira MR; Cardoso, Marta; Paulo, Paula; Maia, Sofia; Teixeira, Manuel R.. "Truncating and Missense PPM1D Mutations in Early-Onset and/or Familial/Hereditary Prostate Cancer Patients.". Genes, Chromosomes and Cancer 55 12 (2016): 954-961. http://europepmc.org/abstract/med/27401275.
    10.1002/gcc.22393
  26. Gusev, Alexander; Shi, Huwenbo; Kichaev, Gleb; Pomerantz, Mark; Li, Fugen; Long, Henry W.; Ingles, Sue A.; et al. "Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation". Nature Communications 7 1 (2016): http://dx.doi.org/10.1038/ncomms10979.
    10.1038/ncomms10979
  27. Silva, Maria P.; Barros-Silva, João D.; Vieira, Joana; Lisboa, Susana; Torres, Lurdes; Correia, Cecília; Vieira-Coimbra, Márcia; et al. "NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer". Genes, Chromosomes and Cancer 55 4 (2016): 365-374. http://dx.doi.org/10.1002/gcc.22340.
    10.1002/gcc.22340
  28. Szulkin R; Karlsson R; Whitington T; Aly M; Gronberg H; Eeles RA; Easton DF; et al. "Genome-wide association study of prostate cancer-specific survival.". (2015): http://europepmc.org/abstract/med/26307654.
    10.1158/1055-9965.EPI-15-0543
  29. Davies, Neil M.; Gaunt, Tom R.; Lewis, Sarah J.; Holly, Jeff; Donovan, Jenny L.; Hamdy, Freddie C.; Kemp, John P.; et al. "The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium". Cancer Causes & Control 26 11 (2015): 1603-1616. http://dx.doi.org/10.1007/s10552-015-0654-9.
    10.1007/s10552-015-0654-9
  30. Szulkin, Robert; Karlsson, Robert; Whitington, Thomas; Aly, Markus; Gronberg, Henrik; Eeles, Rosalind A.; Easton, Douglas F.; et al. "Genome-Wide Association Study of Prostate Cancer–Specific Survival". Cancer Epidemiology Biomarkers & Prevention 24 11 (2015): 1796-1800. http://dx.doi.org/10.1158/1055-9965.epi-15-0543.
    10.1158/1055-9965.epi-15-0543
  31. Maia, Sofia; Cardoso, Marta; Paulo, Paula; Pinheiro, Manuela; Pinto, Pedro; Santos, Catarina; Pinto, Carla; et al. "The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer". Familial Cancer 15 1 (2015): 111-121. http://dx.doi.org/10.1007/s10689-015-9832-x.
    10.1007/s10689-015-9832-x
  32. Szulkin, Robert; Whitington, Thomas; Eklund, Martin; Aly, Markus; Eeles, Rosalind A.; Easton, Douglas; Kote-Jarai, ZSofia; et al. "Prediction of individual genetic risk to prostate cancer using a polygenic score". The Prostate 75 13 (2015): 1467-1474. http://dx.doi.org/10.1002/pros.23037.
    10.1002/pros.23037
  33. Amin Al Olama, Ali; Dadaev, Tokhir; Hazelett, Dennis J.; Li, Qiuyan; Leongamornlert, Daniel; Saunders, Edward J.; Stephens, Sarah; et al. "Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans". Human Molecular Genetics 24 19 (2015): 5589-5602. http://dx.doi.org/10.1093/hmg/ddv203.
    10.1093/hmg/ddv203
  34. Stegeman S; Amankwah E; Klein K; O'Mara TA; Kim D; Lin HY; Permuth-Wey J; et al. "A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.". Cancer Discovery 5 4 (2015): 368-379. http://europepmc.org/abstract/med/25691096.
    10.1158/2159-8290.CD-14-1057
  35. Santos, Joana; Mesquita, Diana; Barros-Silva, João D.; Jerónimo, Carmen; Henrique, Rui; Morais, António; Paulo, Paula; et al. "Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements". Oncoscience 2 5 (2015): 497-507. http://dx.doi.org/10.18632/oncoscience.142.
    10.18632/oncoscience.142
  36. Mesquita, Diana; Barros-Silva, João D.; Santos, Joana; Skotheim, Rolf I.; Lothe, Ragnhild A.; Paulo, Paula; Teixeira, Manuel R.; et al. "Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts". Oncotarget 6 7 (2015): 5217-5236. http://dx.doi.org/10.18632/oncotarget.2847.
    10.18632/oncotarget.2847
  37. Almeida, Mafalda; Costa, Vera L.; Costa, Natália R.; Ramalho-Carvalho, João; Baptista, Tiago; Ribeiro, Franclim R.; Paulo, Paula; et al. "Epigenetic regulation of EFEMP 1 in prostate cancer: biological relevance and clinical potential". Journal of Cellular and Molecular Medicine 18 11 (2014): 2287-2297. http://dx.doi.org/10.1111/jcmm.12394.
    10.1111/jcmm.12394
  38. Al Olama AA; Kote-Jarai Z; Berndt SI; Conti DV; Schumacher F; Han Y; Benlloch S; et al. "A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.". Nature Genetics 46 10 (2014): 1103-1109. http://europepmc.org/abstract/med/25217961.
    10.1038/ng.3094
  39. Barros-Silva, Joao D.; Paulo, Paula; Bakken, Anne Cathrine; Cerveira, Nuno; Løvf, Marthe; Henrique, Rui; Jerönimo, Carmen; et al. "Novel 5' Fusion Partners of ETV1 and ETV4 in Prostate Cancer". Neoplasia 15 7 (2013): 720-IN6. http://dx.doi.org/10.1593/neo.13232.
    10.1593/neo.13232
  40. Eeles, R.A.; Olama, A.A.A.; Benlloch, S.; Saunders, E.J.; Leongamornlert, D.A.; Tymrakiewicz, M.; Ghoussaini, M.; et al. "Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array". Nature Genetics 45 4 (2013): 385-391. http://www.scopus.com/inward/record.url?eid=2-s2.0-84875739291&partnerID=MN8TOARS.
    10.1038/ng.2560
  41. Paulo, Paula; Ribeiro, Franclim R.; Santos, Joana; Mesquita, Diana; Almeida, Mafalda; Barros-Silva, João D.; Itkonen, Harri; et al. "Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements". Neoplasia 14 7 (2012): 600-IN15. http://dx.doi.org/10.1593/neo.12600.
    10.1593/neo.12600
  42. Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; et al. "Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.". (2012): http://europepmc.org/abstract/med/22904677.
  43. Camões, M.J.; Paulo, P.; Ribeiro, F.R.; Barros-Silva, J.D.; Almeida, M.; Costa, V.L.; Cerveira, N.; et al. "Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewing's Sarcoma and Prostate Carcinoma". PLoS ONE 7 11 (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84869748097&partnerID=MN8TOARS.
    10.1371/journal.pone.0049819
  44. Paulo, Paula; Barros-Silva, João D.; Ribeiro, Franclim R.; Ramalho-Carvalho, João; Jerónimo, Carmen; Henrique, Rui; Lind, Guro E.; et al. "FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer". Genes, Chromosomes and Cancer 51 3 (2011): 240-249. http://dx.doi.org/10.1002/gcc.20948.
    10.1002/gcc.20948
  45. Costa, Natália R.; Paulo, Paula; Caffrey, Thomas; Hollingsworth, Michael A.; Santos-Silva, Filipe. "Impact of MUC1 Mucin Downregulation in the Phenotypic Characteristics of MKN45 Gastric Carcinoma Cell Line". PLoS ONE 6 11 (2011): e26970. http://dx.doi.org/10.1371/journal.pone.0026970.
    10.1371/journal.pone.0026970
  46. Ribeiro, Franclim R.; Paulo, Paula; Costa, Vera L.; Barros-Silva, João D.; Ramalho-Carvalho, João; Jerónimo, Carmen; Henrique, Rui; et al. "Cysteine-Rich Secretory Protein-3 (CRISP3) Is Strongly Up-Regulated in Prostate Carcinomas with the TMPRSS2-ERG Fusion Gene". PLoS ONE 6 7 (2011): e22317. http://dx.doi.org/10.1371/journal.pone.0022317.
    10.1371/journal.pone.0022317
  47. Barros, R.; Pereira, B.; Duluc, I.; Azevedo, M.; Mendes, N.; Camilo, V.; Jacobs, R.J.; et al. "Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines". Journal of Pathology 215 4 (2008): 411-420. http://www.scopus.com/inward/record.url?eid=2-s2.0-49449092484&partnerID=MN8TOARS.
    10.1002/path.2369
Preprint
  1. Paulo, Paula; Cardoso, Marta; Brandão, Andreia; Pinto, Pedro; Falconi, Ariane; Pinheiro, Manuela; Cerveira, Nuno; et al. Corresponding author: Teixeira, Manuel. "Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients". 2023. http://dx.doi.org/10.21203/rs.3.rs-2403119/v1.
    10.21203/rs.3.rs-2403119/v1
  2. Andreia Peixoto; Dylan Ferreira; Andreia Miranda; Marta Relvas-Santos; Rui Freitas; Tim S. Veth; Andreia Brandão; et al. "Multilevel Plasticity and Altered Glycosylation Drive Aggressiveness in Hypoxic and Glucose-Deprived Bladder Cancer Cells". 2023. https://doi.org/10.1101/2023.10.21.561355.
    10.1101/2023.10.21.561355
  3. Peixoto, Andreia; Freitas, Rui; Ferreira, Dylan; Relvas-Santos, Marta; Paulo, Paula; Cardoso, Marta; Soares, Janine; et al. "Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation". 2021. http://dx.doi.org/10.1101/2021.02.14.431133.
    10.1101/2021.02.14.431133
  4. Karunamuni RA; Huynh-Le M; Fan CC; Eeles RA; Easton DF; Kote-Jarai Z; Olama AAA; et al. "The effect of sample size on polygenic hazard models for prostate cancer". 2019. http://europepmc.org/abstract/PPR/PPR83280.
    10.1101/679092
  5. Seibert, Tyler M.; Chieh Fan, Chun; Wang, Yunpeng; Zuber, Verena; Karunamuni, Roshan; Kellogg Parsons, J.; Eeles, Rosalind A.; et al. "A genetic risk score to guide age-specific, personalized prostate cancer screening". 2016. http://dx.doi.org/10.1101/089383.
    10.1101/089383
Thesis / Dissertation
  1. "Fusion oncogenes involving the ETS family of transcription factors in prostate cancer: target genes and clinical applications". PhD, Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, 2011.
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2024/01/10 Prostate Cancer Genetics - from bed to bench and back BioMedLab@Talks (https://abiomedlab.org/biomedlabtalks-agenda-trimestral/)
BioMedLab - Associação Portuguesa de Ciências Biomédicas Laboratoriais (Webinar (https://abiomedlab.org), Portugal)
2023/09/15 IPO4 as a new DNA repair gene contributing to inherited prostate cancer predisposition P.CCC Raquel Seruca Workshop
Instituto de Investigação e Inovação em Saúde, Universidade do Porto (Porto, Portugal)
2021/09/24 Pre-clinical exploitation of a combination therapy using a GRPR inhibitor and a tyrosine kinase inhibitor for the treatment of prostate carcinomas with ETV1 rearrangements EMBO Workshop
EMBO (Split, Croatia)
2017/10/02 Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes associated with early-onset/familial prostate cancer 4th Meeting of NGS Platform Users
ILC - Illumina (Porto, Portugal)
2017/03/28 Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes associated with early-onset/familial prostate cancer 11th PRACTICAL/ELLIPSE Meeting
PRACTICAL Consortium (London, United Kingdom)
2014/11/20 Validation of a Next Generation Sequencing pipeline for the molecular diagnosis of multiple inherited cancer predisposition syndromes 18ª Reunião da Sociedade Portuguesa de Genética Humana
Sociedade Portuguesa de Genética Humana (Lisboa, Portugal)
2012/11/23 Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements 16ª Reunião Anual da Sociedade Portuguesa de Genética Humana
Sociedade Portuguesa de Genética Humana (Porto, Portugal)
2010/11/11 The ETS transcription factors ERG and ETV1 activate different downstream target genes in prostate cancer International Life Science Students Conference
Radboud University Nijmegen (Nijmegen, Netherlands)

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2024/01/02 - Current Pre-clinical exploitation of the potential utility of anti-EGFR therapies for the treatment of ETS-positive prostate carcinomas
Supervisor of Elsa Gomes Paiva
 PhD in Biomedical Sciences (PhD)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2023/09/11 - Current Targeting EGFR to modulate primary cilia function in prostate cell lines harbouring ETS rearrangements
Supervisor of Sofia de Oliveira Costa
 Master's Degree in Oncology (Master)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2023/09/04 - Current Exploring the impact of mutations in cilia-related genes in prostate cancer predisposition
Supervisor of Luca Bueno Palhares Rocha
 Master's Degree in Molecular Genetics (Master)
Universidade do Minho, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2016/01/01 - Current Germline mutations in genes involved in the chromosome segregation machinery associated with inherited prostate cancer predisposition
Co-supervisor of Maria Pedro Pessoa de Barros Pereira da Silva
PhD Program in Pathology and Molecular Genetics (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2015/06/01 - 2024/02/23 Recurrent germline mutations in patients with early-onset and/or familial prostate cancer
Co-supervisor of Marta Ribeiro José Cardoso
PhD Program in Pathology and Molecular Genetics (PhD)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022/09/01 - 2023/12/15 In vitro exploitation of the therapeutic potential of EGFR pathway inhibitors in Prostate Cancer cells harboring ETS rearrangements
Supervisor of Elsa Gomes Paiva
 Master in Oncology (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2022/09/01 - 2023/12/06 Exploring overexpression of PEA3 transcription factors as new possible mechanisms of resistance to EGFR targeted therapy in colorectal cancer
Supervisor of Raquel Almeida Ramos
 Master in Oncology (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2020/09/08 - 2021/12/14 Clarifying the role of GRPR and ETV1 overexpression in EGFR-mediated JAK/STAT signaling - putative therapeutic targets for prostate carcinomas with ETV1 rearrangements
Supervisor of Ana Catarina Pinto Azeredo
 Master in Oncology (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2019/04/01 - 2020/12/11 Simultaneous detection of germline and somatic mutations in DNA repair genes by next generation sequencing (NGS) of tumor samples from metastatic prostate cancer patients
Co-supervisor of Ariane Falconi
 Master in Medicine and Molecular Oncology (Master)
Universidade do Porto Faculdade de Medicina, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2011/05/01 - 2012/12/14 Phenotypic impact of ETV4 overexpression in prostate carcinogenesis. (https://sigarra.up.pt/icbas/pt/pub_geral.pub_view?pi_pub_base_id=31060)
Co-supervisor of Diana Sobral Mesquita
 Master in Oncology (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Event organisation

Event name
Type of event (Role) 		Institution / Organization
2023/11/09 - 2023/11/09 1st Young Researchers' Day - This special event was designed with our young IPO researchers in mind, including doctoral students and emerging Ph.D. graduates. Its primary objective was to provide a platform for showcasing the groundbreaking research in the field of oncology, spanning diverse domains. This event opened the doors of IPO-Porto to the broader scientific community and society at large. Overall, 98 researchers have participated, representing 11 research institutions, and 48 scientific works from IPO Porto researchers were presented. (2023/11/09 - 2023/11/09)
Symposium (Member of the Organising Committee)
 Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2023/10/29 - 2023/11/03 Hand-on Course on Generation & Application of Organoid Disease Model
Other
 Generation & Application of Organoid Disease Model
Wellcome Connecting Science, United Kingdom
2022/11/17 - 2022/11/19 26th Annual Meeting of the Portuguese Society of Human Genetics
Meeting
 26ª Reunião Anual da Sociedade Portuguesa de Genética Humana
Sociedade Portuguesa de Genética Humana, Portugal
2021/09/21 - 2021/09/26 EMBO Workshop - Systems approaches in cancer (https://meetings.embo.org/event/20-cancer-systems)
Workshop
 Systems approaches in cancer
Mediterranean Institute for Life Sciences, Croatia
2019/11/12 - 2019/11/14 23rd Meeting of the Portuguese Society of Human Genetics (SPGH)
Meeting
 23ª Reunião Anual da Sociedade Portuguesa de Genética Humana
Sociedade Portuguesa de Genética Humana, Portugal
2019/05/10 - 2019/05/10 GenomePT Symposium
Symposium
 GenomePT Symposium
Universidade do Porto Centro de Investigação em Biodiversidade e Recursos Genéticos, Portugal
2019/04/12 - 2019/04/13 2nd Practical course on computational tools and bioinformatics for next-generation sequencing (16 hours)
Other
 2nd Practical course on computational tools and bioinformatics for next-generation sequencing
Sociedade Portuguesa de Genética Humana , Portugal
2015/11/30 - 2015/12/03 Translational Bioinformatics in Health and Disease - 4-day training course
Other
 Translational Bioinformatics Training Course 2015
Instituto Gulbenkian de Ciência, Portugal
2014/03/13 - 2014/03/14 Partek Software - Start-to-Finish Analysis Solution for NGS and Microarray Data - Training Course
Other
 Partek Training - University of Basel
Partek Inc, United States
2010/10/13 - 2010/10/15 Expression Data Analysis Training Course
Other
 Affymetrix University Expression Data Analysis Training Course
Affymetrix UK Ltd, United Kingdom
2010/09/01 - 2010/09/14 Course in Laboratory Animal Science - Category C with FELASA Accreditation
Other
 Course in Laboratory Animal Science
Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal

Jury of academic degree

Topic
Role 		Candidate name (Type of degree)
Institution / Organization
2023/12/15 In vitro exploitation of the therapeutic potential of EGFR pathway inhibitors in prostate cancer cells harboring ETS rearrangements
Supervisor
 Elsa Gomes Paiva (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2023/12/06 Exploring overexpression of PEA3 transcription factors as new possible mechanisms of resistance to EGFR targeted therapy in metastatic colorectal cancer
Supervisor
 Raquel Almeida Ramos (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2021/12/14 Clarifying the role of GRPR and ETV1 overexpression in EGFR-mediated JAK/STAT signaling – putative therapeutic targets for prostate carcinomas with ETV1 rearrangements
Supervisor
 Ana Catarina Pinto Azeredo (Master)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Ad Hoc journal article review

Journal title (ISSN) Publisher
2022/06/19 - 2023/07/10 Cells (2073-4409) MDPI
2021/04/28 - 2023/04/05 Cancers (2072-6694) Molecular Diversity Preservation International (MDPI)
2022/04/12 - 2022/04/12 Cancer Cell International (1475-2867) BMC
2022/02/19 - 2022/02/19 Breast Cancer Research and Treatment (1573-7217) Springer
2021/07/30 - 2021/07/30 International Journal of Molecular Sciences (1422-0067) MDPI
2021/05/01 - 2021/05/01 Molecules (1420-3049) Molecular Diversity Preservation International (MDPI)
2016/03/30 - 2016/03/30 Cancer Medicine (2045-7634) John Wiley & Sons

Association member

Society Organization name Role
2023/09/19 - Current COST Action IMMUNO-model CA21135 Member of the Working Groups WG1 (In vitro and ex vivo cancer immunotherapy models) and WG3 (Solid tumours)
2022/09/07 - Current The European Association for Cancer Research (EACR) Member (EACR33619)
2022/08/31 - Current Associação Portuguesa de Investigação em Cancro (ASPIC; "Portuguese Association for Cancer Research") Member (ASPIC608)
2019/04/01 - Current Sociedade Portuguesa de Genética Humana (SPGH; "Portuguese Society of Human Genetics") Member (SPGH601)
2016/01/01 - Current Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium Member

Conference scientific committee

Conference name Conference host
2023/02/13 - 2023/02/14 7th Symposium of the MSc in Oncology Portuguese Oncology Institute of Porto

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2020/10/21 - 2020/10/21 Ciência ID Registry (as Ciência ID Institutional Promoter) Curso de Formação Indrodução à Actividade de Investigação CI-IPOP Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil EPE - Escola Portuguesa de Oncologia do Porto, Portugal

Evaluation committee

Activity description
Role 		Institution / Organization Funding entity
2023/09/22 - 2023/09/22 5th Meeting of Young Investigators in Oncology
Evaluator
 Liga Portuguesa Contra o Cancro Núcleo Regional do Centro, Portugal
2022/09/24 - 2022/09/24 4th Meeting of Young Investigators in Oncology
Evaluator
 Liga Portuguesa Contra o Cancro Núcleo Regional do Norte, Portugal Liga Portuguesa Contra o Cancro Núcleo Regional do Centro
2021/09/24 - 2021/09/24 3rd Meeting of Young Investigators in Oncology
Evaluator
 Liga Portuguesa Contra o Cancro Núcleo Regional do Centro, Portugal Liga Portuguesa Contra o Cancro Núcleo Regional do Centro
2020/09/24 - 2020/09/24 2nd Meeting of Young Investigators in Oncology
Evaluator
 Liga Portuguesa Contra o Cancro Núcleo Regional do Norte, Portugal Liga Portuguesa Contra o Cancro Núcleo Regional do Norte

Journal scientific committee

Journal title (ISSN) Publisher
2021/04 - Current Current Issues in Molecular Biology (1467-3045) MDPI
2020/07/01 - Current International Journal of Molecular Sciences (1422-0067) MDPI

Mentoring / Tutoring

Topic Student name
2012/05/01 - 2016/02/22 Oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements: uncovering downstream targets and therapeutic potential Joana Cristina Gouveia Santos
2012/04/01 - 2013/12/20 The role of MYC rearrangements and relative copy number gain in prostate cancer Maria Pedro Pessoa de Barros Pereira da Silva
2012/04/01 - 2013/12/20 The Role of HOXB13 Gene in Breast Cancer Sílvia Isabel Veloso Ramos da Silva Pereira
2012/04/01 - 2013/12/17 The Role of HOXB13 in Prostate Cancer Marta Ribeiro José Cardoso
2012/04/01 - 2013/12/17 The Role of HOXB13 Gene in Colorectal Cancer Miguel Gomes Silva
2008/08/01 - 2010/12/30 Target genes of chimeric ETS transcription factors in Ewing's sarcoma and prostate carcinoma. Maria João Dias Gonçalves Sobral Camões
Distinctions

Award

2023 Revolution Poster Awards by Pierre Fabre (1st Prize)
Pierre Fabre Medicament Portugal LDA, Portugal
2023 Best digital poster in Digestive Cancer
Sociedade Portuguesa de Oncologia, Portugal
2022 Honorable Mention in Clinical Research - Best Poster Communication
Sociedade Portuguesa de Genética Humana, Portugal
2021 Scicare - Novartis Health Science Accelerator
Novartis Farma SA, Portugal
2012 Best Oral Communication in Clinical Investigation (First Prize)
Sociedade Portuguesa de Genética Humana , Portugal
2009 Best Poster Communication (First Prize)
Instituto Português de Oncologia do Porto Francisco Gentil Centro de Investigação, Portugal
2003 Best Finalist Student of the Biotechnology Engineering Course in the year 2002/2003
Instituto Politécnico de Bragança, Portugal
2002 Best Student of the School of Agriculture in the year 2001/2002
Instituto Politécnico de Bragança, Portugal
2001 Best Student of the Biotechnology Engineering Course in the year 2000/2001
Instituto Politécnico de Bragança, Portugal